Clearmind Medicine Inc

Chart & Performance

D1W1MN

P/E

—

P/S

—

EPS

—

Div Yield, %

0.00%

Shrs. gr., 5y

79.79%

Rev. gr., 5y

Revenues

Net income

-12m

L+27.04%

CFO

Profile

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

URL

https://www.clearmindmedicine.com/

IPO date

May 15, 2018

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CAD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title CAD in thousands, except ratios and share amounts	2023‑10	2022‑10	2021‑10	2020‑10	2019‑10	2018‑10	2017‑10
Income
Revenues
Cost of revenue	8,798	8,533
Unusual Expense (Income)
NOPBT	(8,798)	(8,533)
NOPBT Margin
Operating Taxes	24	41
Tax Rate
NOPAT	(8,822)	(8,573)
Net income	(11,955) 27.04%	(9,411) 128.27%
Dividends
Dividend yield
Proceeds from repurchase of equity	8,037	795
BB yield	-1,085.43%
Debt
Debt current		52
Long-term debt		52
Deferred revenue
Other long-term liabilities		1,959
Net debt	(4,005)	(355)
Cash flow
Cash from operating activities		(5,084)
CAPEX		(8)
Cash from investing activities		(8)
Cash from financing activities	8,434	698
FCF	(10,747)	(6,627)
Balance
Cash	4,005	440
Long term investments	284	20
Excess cash	4,005	460
Stockholders' equity	(1,189)	(4,052)
Invested Capital	1,903	2,595
ROIC
ROCE		585.56%
EV
Common stock shares outstanding	202	43
Price	3.66
Market cap	740
EV	(3,265)
EBITDA	(8,756)	(8,419)
EV/EBITDA	0.37
Interest		20
Interest/NOPBT